uniQure (QURE) Stock
uniQure (QURE) closed at $20.78 on Nov 17, 2026; its Tenet Score is 37 of 100 against 340 Healthcare peers.
25 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $20.78
- Nov 17, 2026
- Market cap
- $1.5B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 8.73 – 51.72
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 37/100
- Weak · 340 Healthcare peers
Industry: Drugs
uniQure N.V. scores 37/100. Weak. Strongest on financial health, growth is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
13F flows & insider trades land here.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the tr…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Vir Biotechnology IncVIR | 54 | $1.6B |
| Sarepta Therapeutics IncSRPT | 48 | $1.6B |
| ANI Pharmaceuticals IncANIP | 69 | $1.6B |
| Nurix Therapeutics IncNRIX | 84 | $1.6B |
| SELLAS Life Sciences Group IncSLS | 42 | $1.5B |
| Immunocore Holdings plcIMCR | 53 | $1.5B |
| Pacira BioSciences IncPCRX | 56 | $1.5B |
| Intellia Therapeutics IncNTLA | 41 | $1.4B |
| UroGen Pharma LtdURGN | 44 | $1.4B |
| AlvotechALVO | 41 | $1.4B |
Common questions
What sector and industry is uniQure in?
uniQure is in the Healthcare sector and the Drugs industry.
What is uniQure's Tenet Score?
uniQure's Tenet Score is 37 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




